APOKYN: FDA Approves Mylan's Parkinson's Drug
April 22, 2004

The U.S. Food and Drug Administration approved a first of its kind drug to treat a condition of Parkinson's disease
produced by a subsidiary of Mylan Laboratories Inc., the company said Thursday.

Mylan said the FDA's approval required it to conduct post-marketing studies but said those commitments would not affect
introduction of the drug, Apokyn. Mylan said it planned to begin marketing Apokyn in July.

The medicine is produced by Bertek Pharmaceuticals Inc., Mylan's brand-name subsidiary. Mylan, based in Canonsburg,
Pa., is also a major producer of generic drugs.

Apokyn is said to be the first treatment for hypomobility, a condition of Parkinson's disease that leaves sufferers
partially or totally immobile. Those so-called off periods occur unpredictably and last for varying periods of time.

"This is a significant day for the Parkinson's community and another milestone in Mylan's mission to develop
pharmaceutical products that address unmet medical needs," the company's vice chairman and chief executive, Robert
Coury, said in a statement Thursday.

Apokyn has been given "orphan drug" status, Mylan said. Orphan drugs are designated by the federal government as the
only treatments for conditions affecting fewer than 200,000 people in the United States. Apokyn is Mylan and Bertek's
third orphan drug.

SOURCE: Pittsburgh Business Times, PA
http://tinyurl.com/27twv

* * *

APOKYN: Drug OK'd To Help Patients Immobilized By Parkinson's
UPDATED: 9:21 AM EDT April 23, 2004

WASHINGTON -- The Food and Drug Administration has approved a new drug to treat Parkinson's patients who develop
periods of immobility.

The problem, called hypomobility or "off-periods,'' affects about 10 percent of people with Parkinson's disease, the
agency said Wednesday.

The drug, apomorphine, to be sold under the name Apokyn, was given priority as an orphan drug.

It is the first drug to treat these episodes, which affect about 112,000 people, the agency said.

The FDA said that within three years to five years of treatment with standard Parkinson's drugs, about 10 percent of
patients develop these episodes, when they are unable to rise from a chair, to speak or to walk. The episodes can occur
toward the end of a dosing interval with standard medications or at unpredictable times.

Apokyn, which is injected, can cause severe nausea and must be taken with an anti-nausea drug. Certain anti-nausea
drugs, such as ondansetron, must be avoided because the combination can lead to very low blood pressure and loss of
consciousness.

Apokyn is manufactured for Bertek Pharmaceuticals of Research Triangle Park, N.C., by Draxis Pharma Inc. of Canada.

SOURCE: The Associated Press / NBC 17.com, NC
http://www.nbc17.com/news/3034371/detail.html

Reference:

Bertek: Apokyn to make small moves in market

The FDA has approved the first Parkinson's disease immobility treatment.

April 22, 2004 6:00 PM GMT (Datamonitor) - The FDA has approved Apokyn (apomorphine), an injectable dopamine agonist,
for the treatment of patients with Parkinson's disease (PD) who develop periods of immobility where patients get
'stuck' or 'frozen'. Bertek can expect to draw modest revenues from this niche market, although the positioning will
allow the company to build neurologist relationships while avoiding a clash with big pharma.

Bertek Pharmaceuticals, a subsidiary of Mylan Laboratories [MYL], will market Apokyn, which has orphan drug status in
the US for the relatively rare PD condition known as hypomobility.

Parkinson's is a chronic, progressive condition that leads to tremors, muscle rigidity, slowness, impaired balance and
coordination, and difficulty moving. It is estimated that around 4 million people worldwide suffer from the disease and
the number of patients is expected to grow by 2% per year until 2006. It afflicts both sexes equally, and symptoms
typically appear when people are in their late 50s or early 60s.

Hypomobility, also known as "off-periods," is where patients are unable to move or speak. Although around 1.5 million
Americans suffer from PD, only about 10% develop hypomobility, usually within three to five years of treatment with
standard PD drugs. Given that it is the first drug to be FDA approved for hypomobility, Apokyn will be a welcome
addition to the current armory against this debilitating condition.

The PD market, which was worth over $2.5 billion in 2003, has been revived over the last few years with recent emphasis
on dopamine agonists, which are now recommended as first-line monotherapy.

Although it is a dopamine agonist, apomorphine is used in Europe only as a 'rescue therapy' for severe motor
fluctuations in patients taking levodopa (the gold standard treatment of PD) and there is a good chance that US usage
may follow a similar pattern. Considering the small target population, the inconvenience of an injection, and
apomorphine's poor side effect profile, Bertek can only expect to draw modest revenues from the US market.

Nevertheless, Bertek will benefit from the orphan drug marketing exclusivity period of seven years, allowing the
company time to develop its market presence further. Importantly, positioning its product in this niche sector will
allow Bertek to build a relationship with prescribing neurologists while at the same time avoiding direct competition
with larger market players, which include Pfizer [PFZ.L], GlaxoSmithKline [GSK.L], and Novartis [NVS].

SOURCE: Datamonitor / UK Comment Wire, UK
http://www.commentwire.com/commwire_story.asp?commentwire_ID=5545

- - -

Friday, April 23, 2004

Mylan Laboratories said yesterday that it won approval from the Food and Drug Administration to market Apokyn, a drug
used in the treatment of Parkinson's disease. The drug, an injection, is used to treat patients who have periods of
immobility. It is the first and only therapy approved in the country for treatment of immobility in patients with
advanced Parkinson's disease, Mylan said. A Mylan spokeswoman said the company had not yet projected sales for Apokyn,
which the FDA classified as an orphan drug because it is used to treat a condition in fewer than 200,000 people.

SOURCE: Pittsburgh Post-Gazette
http://www.post-gazette.com/pg/04114/304998.stm

- - -

Orphan Drugs

The term "orphan drug" refers to a product that treats a rare disease affecting fewer than 200,000 Americans. The
Orphan Drug Act was signed into law on January 4, 1983. Since the Orphan Drug Act passed, over 100 orphan drugs and
biological products have been brought to market.

The intent of the Orphan Drug Act is to stimulate the research, development, and approval of products that treat rare
diseases. This mission is accomplished through several mechanisms:

Sponsors are granted seven years of marketing exclusivity after approval of its orphan drug product.

Sponsors also are granted tax incentives for clinical research they have undertaken.

FDA's Office of Orphan Products Development coordinates research study design assistance for sponsors of drugs for rare
diseases [Notice: This link will take you outside the CDER web site].

The Office of Orphan Products Development also encourages sponsors to conduct open protocols, allowing patients to be
added to ongoing studies.

Grant funding is available to defray costs of qualified clinical testing expenses incurred in connection with the
development of orphan products.

SOURCE: FDA
http://www.fda.gov/cder/handbook/orphan.htm

- - -

Definitions of Orphan drug on the Web:
http://tinyurl.com/28goj

* * *

PRESS RELEASE: APOKYN: Accredo Health, Inc. Selected by Bertek as a Preferred Specialty Pharmacy Provider for APOKYN

MEMPHIS, Tenn.--(BUSINESS WIRE)--April 26, 2004--Accredo Health, Incorporated (NASDAQ:ACDO) announced today that its
wholly owned subsidiary, Nova Factor, Inc. has been selected by Bertek Pharmaceuticals, Inc., a wholly owned subsidiary
of Mylan Laboratories, Inc. (NYSE: MYL), as a preferred specialty pharmacy provider of APOKYN(TM) (apomorphine
hydrochloride injection). APOKYN is used in the acute, intermittent treatment of hypomobility, "off" episodes ("end-of-
dose wearing off" and unpredictable "on/off" episodes) associated with advanced Parkinson's disease.

APOKYN is the first therapy approved in the United States for use as an acute (rescue) treatment of "off" episodes.
"Off" episodes are debilitating periods of partial loss of movement or total immobility experienced by patients with
Parkinson's disease.

"We are pleased to begin a relationship with such an outstanding drug manufacturer, while assisting patients with
Parkinson's disease," said David D. Stevens, Accredo's chairman and chief executive officer. "The addition of this
product is another example of the relationships forged by Accredo with the leading manufacturers in the
biopharmaceutical industry."

"We are very excited to bring APOKYN to market, and look forward to providing this product to the Parkinson's
community. Our relationship with Nova Factor, one of three specialty pharmacy providers we have contracted with,
ensures both patients and physicians will have their APOKYN prescription needs fulfilled by a highly respected patient
focused organization," stated James Mauzey, President, Bertek Pharmaceuticals, Inc.

As stated by Bertek, the most common side effects of APOKYN in controlled clinical studies were yawning, dyskinesias,
nausea and/or vomiting, sleepiness, dizziness, runny nose, hallucinations, fluid retention, chest pain, increased
sweating, flushing, and pale complexion.

Accredo's subsidiary, Nova Factor, Inc. has provided specialty pharmaceuticals and quality services for patients with
unique medical needs since 1990. The comprehensive services offered by Nova Factor make it easy for physicians and
other healthcare providers to help patients with APOKYN therapy.

Through Nova Factor's Assignment of Benefits program, an APOKYN-dedicated team of insurance specialists researches
patients' insurance, obtains prior authorization when necessary, files claims on patients' behalf, and bills insurers
directly. The APOKYN team is available to answer questions about product availability and patient services at 1-866-898-
0104. Nova Factor also has an easy fax referral system that can be accessed when the drug is available (fax 1-866-898-
0069).

As part of its service model, Nova Factor's pharmacy team dispenses the drug to the administration location of the
healthcare provider's choice. During a patient's course of therapy, Nova Factor's APOKYN-dedicated team will be a
resource for patients, caregivers, and healthcare professionals to provide information support.

Accredo Health, Incorporated provides specialized pharmacy and related services pursuant to agreements with
biotechnology drug manufacturers relating to the treatment of patients with certain costly, chronic diseases. The
Company's services include collection of timely drug utilization and patient compliance information, patient education
and monitoring through the use of written materials and telephonic consultation, reimbursement expertise and overnight
drug delivery.

In addition to historical information, certain of the statements in the preceding paragraphs, particularly those
anticipating future financial performance, business prospects and growth and operating strategies constitute forward-
looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995. Such statements may be identified by words such as anticipate, believe, estimate, expect, intend, predict,
hope or similar expressions. Such statements, which include estimated financial information or results and the quoted
comments of Mr. Stevens above, are based on management's current expectations and are subject to a number of factors
and uncertainties which could cause actual results to differ materially from those described in the forward-looking
statements, including, without limitation, the loss of a biopharmaceutical relationship, our inability to sell existing
products, difficulties integrating acquisitions, the impact of pharmaceutical industry regulation, the difficulty of
predicting FDA and other regulatory authority approvals, the regulatory environment and changes in healthcare policies
and structure, acceptance and demand for new pharmaceutical products and new therapies, the impact of competitive
products and pricing, the ability to obtain products from suppliers, reliance on strategic alliances, the ability to
expand through joint ventures and acquisitions, the ability to maintain pricing arrangements with suppliers that
preserve margins, the need for and ability to obtain additional capital, the seasonality and variability of operating
results, the Company's ability to implement its strategies and achieve its objectives and the risks and uncertainties
described in reports filed by Accredo with the Securities and Exchange Commission under the Securities Exchange Act of
1934, as amended, including without limitation, cautionary statements under the heading "Risk Factors" made in
Accredo's Annual Report on Form 10-K for its year ended June 30, 2003.

Contacts:

Accredo Health Inc., Memphis

Financial Contact:
Joel Kimbrough, 901-385-3621

or

Investor Relations Contact:
Kerry Finney, 901-381-7442
http://www.accredohealth.com

SOURCE: Business Wire (press release)
http://tinyurl.com/2olac

* * *

PRESS RELEASE: APOKYN: Priority Healthcare is a Preferred Specialty Pharmacy Provider Of Apokyn tm, a New Therapy for
Patients With Parkinson's Disease.

LAKE MARY, Fla., Apr 26, 2004 /PRNewswire-FirstCall via COMTEX/ -- Priority Healthcare Corporation (Nasdaq: PHCC) has
signed an agreement with Bertek Pharmaceuticals, a wholly owned subsidiary of Mylan Laboratories Inc., (NYSE: MYL), to
be a preferred specialty pharmacy provider of Apokyn(TM) (apomorphine hydrochloride injection). Apokyn, approved April
20, 2004 by the FDA, is the first and only therapy in the United States indicated as an acute intermittent treatment of
hypomobility, or "off" episodes, in patients with advanced Parkinson's disease. Apokyn will be available for patient
use in July.

"As both a chronic and progressive disease, Parkinson's disease has a profound affect on the lives of sufferers.
Priority Healthcare is pleased to provide specialty pharmacy services for Apokyn," said Steve Cosler, President and CEO
of Priority Healthcare. "We are happy to establish a relationship with Bertek with this new therapy and pleased to
strengthen our continuing relationship with Mylan Laboratories. Neurology has always been an important area for
Priority Healthcare and this therapy expands our relationship with neurologists and movement disorder specialists."

"We are very excited to bring Apokyn to market, and look forward to providing this product to the Parkinson's
community. Our relationship with Priority Healthcare, one of three specialty pharmacy providers we have contracted
with, ensures both patients and physicians will have their Apokyn prescription needs fulfilled by a highly respected
patient focused organization," stated James Mauzey, President of Bertek Pharmaceuticals, Inc.

Priority Healthcare's specialty pharmacy services for Apokyn will include:

* Caring Paths(TM) disease treatment management process, specific to Parkinson's disease.

* Expert treatment preparation by clinical pharmacists.

* Express shipping direct to homes, physician offices, or other convenient locations.

* Detailed personal instruction and educational materials for self-administration.

* Access to pharmacists and nurses 24 hours a day, 7 days a week, 365 days a year.

* Insurance counseling and assistance through reimbursement specialists who oversee the submission and approval
process.

* Coordination of all aspects of patient care with the physician's office.

About Parkinson's disease

Afflicting the central nervous system, Parkinson's disease is characterized by resting tremors, stiffness in limbs,
slowness of movement, and postural instability. Parkinson's is estimated to affect 1-1.5 million Americans, with
incidence increasing with age. As the disease progresses, patients become less responsive to their medications, such as
levodopa, and may develop motor fluctuations referred to as "off" episodes. "Off" episodes are debilitating periods of
partial loss of movement or total immobility experienced by patients with advanced Parkinson's disease. These episodes
are characterized by stiffness of the limbs, slowness, immobility and, in most cases, tremor. Because patients with
Parkinson's disease lose motor control during "off" episodes, walking, eating, bathing, and even speaking may be more
impaired during an "off" episode.

About Apokyn

Apokyn does not prevent off episodes and does not replace other Parkinson's disease medications, but rather it is used
as an acute (rescue) therapy to effectively treat an off episode when it occurs. Apokyn is given by injection under the
skin. Apokyn should not be used by patients who are being treated with certain drugs to treat nausea and vomiting or
irritable bowel syndrome. These medications (including, for example, ondansetron, granisetron, dolasetron,
palonesetron, and alosetron) called 5HT3 antagonists or blockers. In addition, Apokyn should not be used by patients
who have an allergic reaction to the drug or its ingredients (notably sodium metabisulfite). Apokyn should be injected
under the skin only, and not into a vein. Because Apokyn can cause severe nausea and vomiting, it is taken with an oral
medicine that helps to prevent these effects. Apokyn may lower blood pressure (orthostatic hypotension), cause
fainting, and increase the risk of falling. At recommended doses minimal increases in QTC were observed. Caution should
be used when prescribing apomorphine with drugs that prolong the QT/QTC interval. Some patients treated with Apokyn may
get sleepy during the day or fall asleep without warning while doing everyday activities. The most common side effects
of Apokyn are yawning, dyskinesias, nausea and/or vomiting, sleepiness, dizziness, runny nose, hallucinations, fluid
retention, chest pain, increased sweating, flushing, and an unusually pale complexion.

Additional information on Apokyn is available from Bertek Pharmaceuticals at: www.bertek.com

About Priority Healthcare Corporation

Priority Healthcare Corporation is a national specialty pharmacy and distributor that provides biopharmaceuticals,
complex therapies, and related disease treatment programs and services. Priority Healthcare provides comprehensive
programs for patients, payors, physicians, and pharmaceutical manufacturers for a growing number of disease states
including cancer, hepatitis C, respiratory and pulmonary conditions, infertility, rheumatoid arthritis, hemophilia,
multiple sclerosis, Parkinson's, and age-related macular degeneration. Additional information regarding Priority
Healthcare is available at www.priorityhealthcare.com

Certain statements included in this press release, which are not historical facts, are forward-looking statements. Such
forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. These forward-looking statements represent our expectations or beliefs and involve certain risks and
uncertainties, including those described in our public filings with the United States Securities and Exchange
Commission; also including, but not limited to, changes in interest rates, competitive pressures, changes in customer
mix, changes in third party reimbursement rates, financial stability of major customers, changes in government
regulations or the interpretation of these regulations, changes in supplier relationships, growth opportunities, cost
savings, revenue enhancements, synergies and other benefits anticipated from acquisition transactions, difficulties
relative to integrating acquired businesses, the accounting and tax treatment of acquisitions, and asserted and
unasserted claims, which could cause actual results to differ from those in the forward-looking statements. The forward-
looking statements by their nature involve substantial risks and uncertainties, certain of which are beyond our
control, and actual results may differ materially depending on a variety of important factors. You are cautioned not to
place undue reliance on these forward-looking statements that speak only as of the date herein.

SOURCE: Priority Healthcare Corporation

CONTACT:

Financial: Stephen Saft,
Chief Financial Officer,
+1-407-804-6700
Priority Healthcare Corporation

Media: Kirsten Ayars,
Public Relations Manager,
+1-407-804-5826
Priority Healthcare Corporation

/Photo:  http://www.newscom.com/cgi-bin/prnh/20030417/PHCLOGO

URL:

http://www.priorityhealthcare.com
http://www.prnewswire.com

SOURCE: PRNewsWire / Macro*World Investor
http://www.mworld.com/m/m.w?lp=GetStory&id=92909261

* * *

PRESS RELEASE: Mylan Announces FDA Approval Of APOKYN NDA; A Novel Treatment in Parkinson's Disease.

PITTSBURGH, Apr 22, 2004 (BUSINESS WIRE) -- Mylan Laboratories Inc. (NYSE: MYL) announced that its branded-drug
subsidiary, Bertek Pharmaceuticals Inc., received notice from the Food and Drug Administration (FDA) following their
priority review that APOKYN(TM) (apomorphine hydrochloride injection) has been approved as the first and only therapy
in the United States for the acute, intermittent treatment of hypomobility, "off" episodes ("end-of-dose wearing off"
and unpredictable "on/off" episodes) associated with advanced Parkinson's disease.

"This is a significant day for the Parkinson's community and another milestone in Mylan's mission to develop
pharmaceutical products that address unmet medical needs," said Robert J. Coury, Mylan Vice Chairman and CEO.

The FDA approval clears the way for Bertek to market APOKYN and provides a new therapy for "off" episodes, one of the
most debilitating aspects suffered by patients with Parkinson's disease. The approval includes post marketing study
commitments, but will not impact market introduction of this important product. The product will be available by July
2004 and distributed through a limited specialty pharmacy network. APOKYN has orphan drug status, a federal designation
to indicate the drug's exclusive use in treating a condition affecting fewer than 200,000 people in the United States.
APOKYN will be the third orphan drug marketed by Mylan and Bertek.

About APOKYN

APOKYN provides patients with an effective treatment to use during an 'off' episode. "Off" episodes are debilitating
periods of partial loss of movement or total immobility experienced by patients with advanced Parkinson's disease. As
Parkinson's disease progresses, patients begin to experience immobilizing "off" episodes despite treatment with drugs
used to increase or replace dopamine. APOKYN is not used to prevent "off" episodes and it does not replace other
Parkinson's disease medications, but rather treats an existing "off" episode when it occurs. As an acute, rescue
treatment, APOKYN helps patients experiencing a debilitating "off" episode to walk, talk or move around easier. The
intensity, duration and frequency of "off" episodes vary for each sufferer. Patients with Parkinson's disease lose
motor control during "off" episodes, making routine tasks such as walking and even speaking extremely difficult.
Patients with Parkinson's or their caregivers administer the medication via injection under the skin.

"These debilitating effects are known all too well by patients experiencing 'off' episodes," said Dr. Mark Stacy,
director of the Movement Disorders Section at Duke University Medical Center. "With the FDA approval of APOKYN, I can
now offer patients an effective treatment to relieve them from these immobilizing 'off' episodes."

In clinical trials conducted by Bertek, APOKYN was effective in improving an overall measurement of patient movement.
"The data from clinical trials show that APOKYN, when used in conjunction with standard pharmacological therapies for
Parkinson's disease, has the ability to provide relief from an 'off' episode," said Dr. James H. Sherry, Vice President
of Clinical Affairs at Bertek Pharmaceuticals Inc. "This is a new way for Parkinson's patients to reduce some of the
burden of their disease."

The effectiveness of APOKYN for the acute treatment of "off" episodes associated with advanced Parkinson's disease was
established in three randomized controlled clinical trials. Patients who received APOKYN demonstrated statistically
significant improvement in their Unified Parkinson's disease Rating Scale part III (UPDRS) motor score at 20-minutes
following the administration of the drug compared to a placebo injection. The UPDRS is used by researchers and
clinicians around the world to measure disease severity in patients.

Important Information

APOKYN should not be used by patients who are being treated with certain drugs to treat nausea and vomiting or
irritable bowel syndrome. These medications (including, for example, ondansetron, granisetron, dolasetron,
palonesetron, and alosetron) called 5HT3 antagonists or blockers. In addition, APOKYN should not be used by patients
who have an allergic reaction to the drug or its ingredients (notably sodium metabisulfite). APOKYN should be injected
under the skin only, and not into a vein. Because APOKYN can cause severe nausea and vomiting, it is taken with an oral
medicine that helps to prevent these effects. APOKYN may lower blood pressure (orthostatic hypotension), cause
fainting, and increase the risk of falling. At recommended doses minimal increases in QTC were observed. Caution should
be used when prescribing apomorphine with drugs that prolong the QT/QTC interval. Some patients treated with APOKYN may
get sleepy during the day or fall asleep without warning while doing everyday activities. The most common side effects
of APOKYN are yawning, dyskinesias, nausea and/or vomiting, sleepiness, dizziness, runny nose, hallucinations, fluid
retention, chest pain, increased sweating, flushing, and an unusually pale complexion.

About Bertek

Bertek Pharmaceuticals Inc., based in Research Triangle Park, N.C., develops and licenses proprietary pharmaceuticals,
with a current focus on dermatology, neurology and cardiology. For more information, visit http://www.bertek.com

About Mylan

Mylan Laboratories Inc. is a leading pharmaceutical company with four subsidiaries, Mylan Pharmaceuticals Inc., Mylan
Technologies Inc., UDL Laboratories Inc. and Bertek Pharmaceuticals Inc., that develop, manufacture and market an
extensive line of generic and proprietary products. For more information about Mylan, visit www.mylan.com.

This press release includes statements that constitute "forward-looking statements," including with regard to the
availability and use of APOKYN. These statements are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual
future results may differ materially from those expressed or implied by such forward-looking statements. Factors that
could cause or contribute to such differences include, but are not limited to: delays in the product launch, including
due to matters outside of the Company's control; the Company's exposure to lawsuits and contingencies associated with
its business; other uncertainties and matters beyond the control of management and the other risks detailed in the
Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update
these statements for revisions or changes after the date of this release.

SOURCE: Mylan Laboratories Inc.

CONTACT:

Mylan Laboratories Inc.

Public Relations:
Heather Bresch
724-514-1800

or:

Investor Relations:
Kris King, 724-514-1800

SOURCE: Business Wire / Macro*World Investor
http://www.mworld.com/m/m.w?lp=GetStory&id=92318161

* * *

----------------------------------------------------------------------
To sign-off Parkinsn send a message to: mailto:[log in to unmask]
In the body of the message put: signoff parkinsn